Reply

Autor:	Vedran Pavlovic, Edward Gane, Ben Fillippo Krippendorff, Joseph F. Grippo, S Ottosen, Cynthia Wat, Man-Fung Yuen, Henrik Mueller
Rok vydání:	2021
Předmět:	carbohydrates (lipids) HBsAg Messenger RNA Hepatitis B Chronic Hepatology business.industry Oligonucleotides Humans Potency Medicine Pharmacology business Healthy Volunteers
Zdroj:	Hepatology. 75:1050-1051
ISSN:	1527-3350 0270-9139
DOI:	10.1002/hep.32113
Popis:	Firstly, Dr Vaillant proposes RO7062931 should have exhibited greater HBsAg reductions, given the efficient RO7062931 liver uptake, rapid turnover of HBsAg, and rapid protein reductions observed with GalNAc-ASOs in other therapeutic indications. We find this reasoning unsatisfactory, primarily as there should be no expectations of similar potency for GalNAc-ASOs targeting different mRNA species.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d96da46efdb22357a58667b750aa1ea6 https://doi.org/10.1002/hep.32113 Zobrazit plný text záznamu Plný text